What the July 2026 FDA Expansion Means for Men with Advanced Prostate Cancer
Sharp Memorial offers new treatment for advanced prostate cancer – NBC 7 San Diego
Pluvicto Moves Earlier:
A San Diego Navy veteran's story, the research behind the headlines, and the questions to bring to your next oncology visit.
Bottom Line Up Front
- On July 31, 2026, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), given together with a modern hormone pill (an ARPI), for men whose PSMA-positive prostate cancer has spread but still responds to hormone therapy. Until now, Pluvicto was limited to men whose cancer had stopped responding to hormones. Novartis says the change nearly doubles the number of eligible men.
- The approval rests on the PSMAddition trial of 1,144 men. Adding Pluvicto to standard hormone therapy lowered the risk of cancer progression or death by 28% at the primary analysis and by 33% at an updated analysis. A survival advantage is trending in Pluvicto's favor but is not yet proven; final survival results are still to come.
- Serious (grade 3 or higher) side effects were somewhat more common with Pluvicto (about 51% versus 43%), mostly low blood counts, while quality of life was similar in both groups. Dry mouth, fatigue, and nausea are the most familiar complaints.
- You must have a PSMA PET scan showing that your cancer "lights up" before you can receive Pluvicto. Treatment is one IV dose every six weeks, for up to six doses, at centers such as Sharp Memorial Hospital here in San Diego.
- Stronger "alpha-particle" versions of this approach (actinium-225) are in early trials and look promising, but they are not yet approved.
A Promise Made 64 Years Ago
Harry Chilton met his wife, Sharon, in high school when he was 16. They have now been married 64 years. This month, NBC 7 San Diego reported that the Navy veteran, who turned 83 during the week of the broadcast, has begun Pluvicto treatment at Sharp Memorial Hospital for stage 4 prostate cancer that has spread to his bones. Hormone treatments had stopped working for him.
His reason for pressing on is simple. Sharon's memory is failing, and he wants to be there to care for her. "Sharon was there for me," he told NBC 7. "It's my turn for me to be here for her."
Many IPCSG members will recognize themselves, or someone they love, in that sentence. So it is worth looking carefully at what Pluvicto is, what the evidence actually shows, and what changed this summer.
What Pluvicto Is, in Plain Terms
Most prostate cancer cells carry a protein on their surface called PSMA (prostate-specific membrane antigen). Pluvicto is a "radioligand," a small targeting molecule that seeks out PSMA and carries a tiny dose of radioactive lutetium-177 with it. Once it latches onto a cancer cell, the lutetium releases beta radiation that damages that cell and its close neighbors.
Dr. Joshua Rosenbaum, the Sharp Memorial radiologist who helped build the hospital's program when it began in 2025, described it to NBC 7 this way: the medicine circulates through the body, finds the cancer, and attaches to it, so the radiation lands mainly on the cancer rather than on healthy tissue.
Engineers in our group will recognize the logic. The PSMA PET scan is the "search radar" that finds and confirms the target; Pluvicto is the guided round that homes on the same signature. The two use the same target, which is why doctors call the pairing "theranostics" (therapy plus diagnostics).
How We Got Here: Three FDA Decisions in Four Years
Pluvicto has moved steadily earlier in the course of advanced prostate cancer, each step backed by a large randomized trial.
| FDA decision | Who became eligible | Key trial and headline result |
|---|---|---|
| March 2022 | PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) already treated with a hormone pill and chemotherapy | VISION (831 men): median survival 15.3 vs 11.3 months; 38% lower risk of death |
| March 28, 2025 | PSMA-positive mCRPC after one hormone pill, in men appropriate to delay chemotherapy | PSMAfore: 59% lower risk of progression or death; median time before progression more than doubled (11.6 vs 5.6 months, updated analysis) |
| July 31, 2026 | PSMA-positive metastatic cancer that still responds to hormone therapy (now called mAPMN/S; formerly mHSPC), given with a hormone pill | PSMAddition (1,144 men): 28% lower risk of progression or death (33% at updated analysis); survival trend favorable but not yet final |
A note on the new jargon: the FDA's July announcement uses the term "metastatic androgen pathway modulation-naïve or -sensitive" (mAPMN/S) prostate cancer. It means the same thing most of us have long called metastatic hormone-sensitive prostate cancer (mHSPC): cancer that has spread but has not yet become resistant to hormone therapy.
Inside the PSMAddition Trial
PSMAddition was the first phase 3 trial of a radioligand therapy in men whose metastatic cancer still responds to hormones. Researchers randomly assigned 1,144 men with at least one PSMA-positive metastasis on PET scan to one of two groups:
- Standard therapy, meaning androgen deprivation therapy (ADT, such as Lupron) plus an androgen receptor pathway inhibitor (ARPI, such as abiraterone, enzalutamide, apalutamide, or darolutamide).
- The same standard therapy plus Pluvicto, one dose every six weeks for up to six doses.
Men in the standard group were allowed to switch to Pluvicto if their cancer progressed. That is good for the individual patient, but it makes survival comparisons harder to read, because many "control" patients eventually received the drug too. Dr. Scott Tagawa of Weill Cornell, who presented the results at the European Society for Medical Oncology meeting in October 2025, noted that about 60% of control-group men with confirmed progression had crossed over by the time of that early analysis.
What the numbers show
Radiographic progression-free survival (how long men lived without their cancer visibly growing on scans) was the main goal. At the primary analysis the hazard ratio was 0.72, a 28% reduction in risk. An updated analysis cited in the FDA approval improved that to 0.67, a 33% reduction. Median values had not yet been reached in either group, which is itself a reminder that many men in this earlier stage do well for years on standard therapy.
Overall survival is trending toward benefit (hazard ratio 0.80), but the statistical range still crosses 1.0, so it is not yet proven. Novartis says the data are still maturing ahead of a final survival analysis. Patients should hear this plainly: the approval is based on delaying progression, and the survival question remains open.
Side effects: Grade 3 or worse side effects occurred in 50.7% of men receiving Pluvicto versus 43.0% on standard therapy alone. The most common side effects of any grade were dry mouth, fatigue, nausea, hot flashes, and anemia. Importantly, quality-of-life measures were similar between the two groups over time.
"The treatment landscape for [metastatic hormone-sensitive prostate cancer] is evolving, and this approval reflects a growing recognition that earlier treatment intensification matters."
Dr. Michael J. Morris, Memorial Sloan Kettering, U.S. principal investigator of PSMAddition
Who Qualifies, and How
Pluvicto only works if your cancer carries enough PSMA. The FDA label requires selection with Locametz (gallium Ga 68 gozetotide) or another approved PSMA PET imaging agent. If your cancer does not show up well on the PSMA PET scan, Pluvicto is unlikely to help, and other treatments will be the better path.
Under the three approvals, Pluvicto is now available at each stage of metastatic disease:
- Newly metastatic, hormone-sensitive disease, alongside ADT and an ARPI (new in July 2026).
- Castration-resistant disease after one ARPI, before chemotherapy (2025).
- Castration-resistant disease after an ARPI and chemotherapy (2022).
Pluvicto is not approved for localized cancer or for men with a rising PSA and no visible metastases.
Safety: What to Watch For
Pluvicto is generally well tolerated, but it is radiation, and it carries real risks that your care team will monitor:
- Dry mouth occurs because the salivary glands also take up PSMA-targeting drugs. It is usually mild but can linger.
- Low blood counts (anemia, low platelets, low white cells) are the most common serious side effects. Expect regular blood tests.
- Kidney effects are possible, so kidney function is checked and good hydration is encouraged.
- Fertility and radiation precautions: the treatment can affect fertility, and for a short period after each dose you will receive instructions to limit close contact with others, especially children and pregnant women.
Why It Matters Now
The American Cancer Society estimates about 333,830 new prostate cancer cases and about 36,320 deaths in the United States in 2026. Roughly 1 man in 8 will be diagnosed during his lifetime, and about 1 in 44 will die of the disease.
The trend that concerns patient advocates most is the rise in advanced disease. ACS's 2025 prostate cancer statistics report found that diagnoses of advanced-stage cancer have been increasing by roughly 4.6% to 4.8% per year, and that five-year survival for distant-stage disease is about 38%, compared with nearly 100% for cancer caught early. More men arriving with metastatic disease means more men who may now be candidates for earlier Pluvicto.
Supply was a real problem when Pluvicto first launched. Novartis now reports five U.S. radioligand manufacturing sites either operating or under construction, and says it can meet the larger demand from the new approval.
What's Coming Next
Alpha emitters: a bigger punch at shorter range
Lutetium-177 emits beta particles, which travel a few millimeters in tissue. Alpha emitters such as actinium-225 deliver far more energy over a much shorter distance, which may help when cancer has become resistant to lutetium. At the 2026 ASCO meeting, Dr. Louise Emmett presented the phase 1 AcTION trial of actinium-225 PSMA-617, the first prospective study of this agent. Doses up to 10 MBq were tolerable, with no dose-limiting toxicities and no maximum tolerated dose reached, and PSA and scan responses were seen whether or not men had previously received lutetium therapy. Other alpha programs, including CONVERGE-01 (Ac-225 rosopatamab) and FL-020, are in early testing. None of these is approved; they are available only through clinical trials.
More lutetium options
Curium's lutetium-177 PSMA-I&T met its main goal in the phase 3 ECLIPSE trial in 2024, in men with castration-resistant disease before chemotherapy. The company has said it is working with the FDA on a regulatory plan. Readers should ask their oncologist about its current status, since it has not been reported as approved.
Questions to Bring to Your Oncologist
- Has my cancer been checked with a PSMA PET scan, and is it PSMA-positive enough for Pluvicto?
- Given where I am in my disease, would adding Pluvicto now be likely to help me more than saving it for later?
- How would it fit with my current hormone therapy, and what blood and kidney monitoring will I need?
- What does my insurance or Medicare cover, and where is the nearest treatment center?
- Am I a candidate for a clinical trial of an alpha-emitter or another next-generation radioligand?
A Few Terms, Defined
- PSMA
- Prostate-specific membrane antigen, a protein found in high amounts on most prostate cancer cells.
- ADT
- Androgen deprivation therapy; shots or pills that lower testosterone (for example, Lupron or Orgovyx).
- ARPI
- Androgen receptor pathway inhibitor; newer hormone pills such as abiraterone (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada), or darolutamide (Nubeqa).
- mCRPC
- Metastatic castration-resistant prostate cancer; cancer that has spread and keeps growing despite low testosterone.
- mHSPC / mAPMN/S
- Metastatic cancer that still responds to hormone therapy. mAPMN/S is the newer FDA term.
- Hazard ratio (HR)
- A comparison of risk between two groups. An HR of 0.72 means a 28% lower risk of the event in the treated group.
Harry Chilton put the stakes better than any statistic can. "I was ready to go," he said. "But, now I need to be here for awhile." For men like Harry, and for the families who depend on them, a treatment that buys time with manageable side effects is not an abstraction. The July approval means more men can ask whether it is right for them, earlier.
Sources
- Perez MG. Prostate Cancer Awareness Month: new hope for men with medicine injections. NBC 7 San Diego. September 2026. https://www.nbcsandiego.com/news/local/prostate-cancer-awareness-month-new-hope-men-with-medicine-injections/4075720/
- U.S. Food and Drug Administration. FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. July 31, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy
- Novartis. FDA approves Pluvicto® for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease [press release]. Basel; July 31, 2026. https://www.novartis.com/news/media-releases/fda-approves-pluvicto-psma-metastatic-hormone-sensitive-prostate-cancer-mhspc-advancing-potential-new-standard-care-across-metastatic-disease
- Healio. FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer. August 3, 2026. https://www.healio.com/news/hematology-oncology/20260803/fda-approves-pluvicto-for-psmapositive-metastatic-hormonesensitive-prostate-cancer
- CURE. FDA approves Pluvicto plus hormone therapy for certain patients with metastatic prostate cancer. 2026. https://www.curetoday.com/view/fda-approves-pluvicto-plus-hormone-therapy-for-certain-patients-with-metastatic-prostate-cancer
- Oncology Nursing News. FDA approves Pluvicto for PSMA+ mAPMN/S prostate cancer. August 1, 2026. https://www.oncnursingnews.com/view/fda-approves-pluvicto-for-psma-mapmn-s-prostate-cancer
- Tagawa ST, Sartor O, Piulats JM, et al. Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Presented at: ESMO Congress 2025; October 19, 2025; Berlin, Germany. Abstract LBA6. Summary: https://www.urotoday.com/conference-highlights/esmo-2025/esmo-2025-prostate-cancer/164097-esmo-2025-phase-iii-trial-of-177lu-lu-psma-617-combined-with-adt-arpi-in-patients-with-psma-positive-metastatic-hormone-sensitive-prostate-cancer-psmaddition.html
- OncLive. Dr Tagawa on the efficacy of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in PSMA+ mHSPC. November 6, 2025. https://www.onclive.com/view/dr-tagawa-on-the-efficacy-of-lutetium-lu-177-vipivotide-tetraxetan-plus-arpi-and-adt-in-psma-mhspc
- Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322. https://doi.org/10.1056/NEJMoa2107322
- U.S. Food and Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer. March 23, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer
- Morris MJ, Castellano D, Herrmann K, et al; PSMAfore Investigators. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227-1239. doi:10.1016/S0140-6736(24)01653-2. https://doi.org/10.1016/S0140-6736(24)01653-2
- U.S. Food and Drug Administration. FDA expands Pluvicto's metastatic castration-resistant prostate cancer indication. March 28, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication
- Novartis. FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer [press release]. Basel; March 28, 2025. https://www.novartis.com/news/media-releases/fda-approves-novartis-radioligand-therapy-pluvicto-earlier-use-chemotherapy-psma-positive-metastatic-castration-resistant-prostate-cancer
- American Cancer Society. Key statistics for prostate cancer. Last revised January 13, 2026. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
- American Cancer Society. New ACS prostate cancer statistics report: late-stage incidence rates continue to increase rapidly as mortality declines slow [press release]. September 2, 2025. (Report published in CA: A Cancer Journal for Clinicians.) https://www.biospace.com/press-releases/new-acs-prostate-cancer-statistics-report-late-stage-incidence-rates-continue-to-increase-rapidly-as-mortality-declines-slow
- Emmett L, et al. AcTION: phase 1 study of [225Ac]Ac-PSMA-617 in men with metastatic castration-resistant prostate cancer with or without prior [177Lu]Lu-PSMA radioligand therapy. J Clin Oncol. 2026;44(16 suppl):5010. doi:10.1200/JCO.2026.44.16_suppl.5010. Report: Urology Times. https://www.urologytimes.com/view/phase-1-action-trial-establishes-rp2d-for-225ac-psma-617
- UroToday. ASCO 2026: Discussant, moving beyond beta-emitters: the next generation radioligand therapies in prostate cancer (Calais J). June 2026. https://www.urotoday.com/conference-highlights/asco-2026/asco-2026-prostate-cancer/169613-asco-2026-discussant-moving-beyond-beta-emitters-the-next-generation-radioligand-therapies-in-prostate-cancer.html
- Curium. Curium announces ECLIPSE trial has met primary endpoint, demonstrating a statistically significant and clinically meaningful benefit for patients with PSMA-positive metastatic castration resistant prostate cancer [press release]. November 13, 2024. https://www.curiumpharma.com/2024/11/13/eclipse-tiral-psma-prostate-cancer/
This article is for education and support only and is not medical advice. Treatment decisions depend on your individual situation; please discuss them with your oncology team. IPCSG does not endorse any specific product or manufacturer.
Comments
Post a Comment